Specifications of a continual reassessment method design for phase I trials of combined drugs

被引:29
作者
Wages, Nolan A. [1 ]
Conaway, Mark R. [1 ]
机构
[1] Univ Virginia, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, VA USA
关键词
continual reassessment method; dose finding; maximum tolerated dose; phase I trials; partial ordering; drug combination; ADVANCED SOLID TUMORS; COMBINATIONS;
D O I
10.1002/pst.1575
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In studies of combinations of agents in phase I oncology trials, the dose-toxicity relationship may not be monotone for all combinations, in which case the toxicity probabilities follow a partial order. The continual reassessment method for partial orders (PO-CRM) is a design for phase I trials of combinations that leans upon identifying possible complete orders associated with the partial order. This article addresses some practical design considerations not previously undertaken when describing the PO-CRM. We describe an approach in choosing a proper subset of possible orderings, formulated according to the known toxicity relationships within a matrix of combination therapies. Other design issues, such as working model selection and stopping rules, are also discussed. We demonstrate the practical ability of PO-CRM as a phase I design for combinations through its use in a recent trial designed at the University of Virginia Cancer Center. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 18 条
[1]   A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma [J].
Berenson, James R. ;
Yellin, Ori ;
Patel, Ravi ;
Duvivier, Herb ;
Nassir, Youram ;
Mapes, Russell ;
Abaya, Christina DiLauro ;
Swift, Regina A. .
CLINICAL CANCER RESEARCH, 2009, 15 (03) :1069-1075
[2]   Designs for single- or multiple-agent phase I trials [J].
Conaway, MR ;
Dunbar, S ;
Peddada, SD .
BIOMETRICS, 2004, 60 (03) :661-669
[3]  
Heyd JM, 1999, STAT MED, V18, P1307, DOI 10.1002/(SICI)1097-0258(19990615)18:11<1307::AID-SIM128>3.0.CO
[4]  
2-X
[5]  
Korn EL, 1995, STAT MED, V15, P1799
[6]   Model calibration in the continual reassessment method [J].
Lee, Shing M. ;
Cheung, Ying Kuen .
CLINICAL TRIALS, 2009, 6 (03) :227-238
[7]   Non-parametric optimal design in dose finding studies [J].
O'Quigley, J ;
Paoletti, X ;
Maccario, J .
BIOSTATISTICS, 2002, 3 (01) :51-56
[8]   A stopping rule for the continual reassessment method [J].
O'Quigley, J ;
Reiner, E .
BIOMETRIKA, 1998, 85 (03) :741-748
[9]   Retrospective Robustness of the Continual Reassessment Method [J].
O'Quigley, John ;
Zohar, Sarah .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (05) :1013-1025
[10]   CONTINUAL REASSESSMENT METHOD - A PRACTICAL DESIGN FOR PHASE-1 CLINICAL-TRIALS IN CANCER [J].
OQUIGLEY, J ;
PEPE, M ;
FISHER, L .
BIOMETRICS, 1990, 46 (01) :33-48